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Abstract
Introduction: The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of 
risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to 
receive anastrozole (A).
Methods: Pre-treatment BMD of 213 patients with hormone receptor-positive BC was evaluated at lumbar spine (LS) 
and hip (HP). Patients were categorized according to their baseline BMD T-score as being at low, moderate and high 
risk of osteoporosis. Low risk patients received anastrozole only (A), moderate risk were randomized to anastrozole +/- 
risedronate (A+/-R) administration and high risk patients received anastrozole + risedronate (A+R). Anastrozole was 
given at a dosage of 1 mg/day while oral risedronate was given at 35 mg/week. BMD was then assessed at 12 and 24 
months. All patients received daily supplements of calcium (1000 mg/day) and vitamin D (400 IU/day).
Results: At 24 months, in the moderate risk group, treatment with A+R resulted in a significant increase in BMD at LS 
and HP compared to treatment with A only (5.7% v -1.5%, Wilcoxon test P = 0.006, and 1.6% v -3.9% Wilcoxon test P = 
0.037, respectively), while no significant difference was found at 12 months; 24.3% of the patients moved to normal 
BMD region. In the high risk group, a significant increase for LS was detected both at 12 and 24 months (6.3% and 6.6%, 
P < 0.001) but not for HP; BMD in 14% of patients improved to the osteopenic region. In the low risk group, a significant 
decrease of BMD was detected at 12 months for LS and HP (-5.3% P < 0.001 and -2.4% P < 0.001, respectively,); at 24 
months, a significant decrease of BMD was detected only for LS (-2.5%, P < 0.001). However, 22% of patients became 
osteopenic and only 4% became osteoporotic.
Conclusions: The addition of oral risedronate in post-menopausal breast cancer patients receiving anastrozole has a 
favorable effect on BMD. Patients with pre-treatment osteopenic to osteoporotic status should be treated with a 
combination of both therapies in order to avoid bone loss induced by aromatase inhibition. Patients with normal BMD 
before starting treatment with anastrozole have a very low risk to develop osteoporosis.
Trial registration: ClinicalTrials.gov Identifier NCT00809484.
Introduction
More than 70% of breast cancer patients develop endo-
crine-responsive disease with estrogen receptor (ER)-
positive or progesterone receptor-positive tumors or
both [1] and require endocrine treatment with either
estrogen blockage or ablation. On the other hand, it is
well known that estrogens have an indirect and positive
effect on bone metabolism by stimulating the production
of several cytokines acting either as inhibitors of osteo-
clastogenesis or as antireceptive agents leading active
osteoclasts to apoptosis [2]. Therefore, the depletion of
estrogens in patients with endocrine-responsive breast
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cancer leads to increased bone resorption and finally
osteoporosis occurs, resulting in increased risk for bone
fractures [3,4].
The introduction of aromatase inhibitors (AIs) during
the last decade has opened new horizons in the successful
treatment of ER-positive breast cancer. Clinical trials
established the role of AIs in the adjuvant therapy of post-
menopausal women with hormone-responsive breast
cancer in upfront, switch, and sequential treatment set-
tings [5] and this is reflected by international guidelines
such as those of the American Society of Clinical Oncol-
ogy [6], St. Gallen [7], the National Comprehensive Can-
cer Network [8], and others.
However, various clinical studies demonstrated that
estrogen deprivation caused by AI administration has a
serious negative effect on bone health [9]. Bone mineral
density (BMD) rapidly decreases with a consequent high
risk of skeletal fragility due to aromatase inhibitor-associ-
ated bone loss (AIBL). For the prevention of this adverse
event, antiresoptive agents such as bisphosphonates (BPs)
are used in combination with AIs.
BPs have a high affinity for hydroxyapatite, bind
directly to mineralized bone, and enable the bone to be
resistant to endogenous phosphatases [10]. On osteoclast
s t im u la t io n of  bone  r esorp ti on,  t he  B P is  r e leased and
internalized by the osteoclasts, interfering with osteoclast
formation, function, and survival [11]. Various com-
pounds of BPs, available for either oral or intravenous
administration, can have a beneficial effect on tumor-
induced osteolysis, thereby minimizing the destructive
consequences of estrogen deficiency-associated osteopo-
rosis. However, oral BPs can be administered at home in
weekly or monthly formulations, offering convenience for
patients and, in this respect, could be the ideal treatment
for the prevention of skeletal complications in early
breast cancer patients with no evidence of metastatic
spread to bones.
Arimidex Bone Mass Index and Oral Bisphosphonates
(ARBI) is a phase III, multicenter, open-label clinical trial
conducted by the Hellenic Society of Breast Surgeons.
The primary aims of this study were to investigate the
effect of risedronate on BMD changes from baseline in
postmenopausal, early breast cancer patients receiving
anastrozole with follow-up from baseline to 24 months
and to evaluate the effect of anastrozole monotherapy on
b o n e  m a s s  i n  a  g r o u p  o f  p a t i e n t s  w i t h  n o r m a l  B M D
before starting treatment.
Materials and methods
A total of 213 consecutive eligible postmenopausal
patients who had histologically confirmed hormone
receptor-positive breast cancer and who had completed
primary surgery and chemotherapy (if indicated) and
were scheduled to receive anastrozole were enrolled in
the ARBI study. Patients were excluded if their meno-
pause was induced by prior chemotherapy or any other
drug therapy, and other exclusion criteria were evidence
of metastatic bone disease by bone scans, previous hip
(HP) fractures or prostheses, known bone metabolism
disorder, non-treated hypocalcemia, and previous treat-
ment with selective estrogen receptor modulators
(SERMs), hormone-replacement therapy (HRT), or BPs
and liver or renal dysfunction.
The primary endpoint of the study was to investigate
the effect of risedronate in patients with mild osteopenia
(randomized arms) receiving anastrozole therapy, mea-
sured in both lumbar spine (LS) and HP at 12 months,
and the secondary endpoint was the investigation of this
effect at 24 months. Other secondary endpoints were (a)
to evaluate the effect of anastrozole on BMD in patients
with normal BMD before starting treatment and (b) to
investigate the effect of risedronate in patients receiving
anastrozole therapy who have BMD in the region of
severe osteopenia or osteoporosis.
Pre-treatment baseline BMD was evaluated at LS and
HP by dual-energy x-ray absorptiometry (DEXA) and
then was assessed at both sites at 12 and 24 months. All
baseline and follow-up measurements of 170 patients
(79.8%) were centrally performed in one referral center in
Athens (type of absorptiometer: Explorer made by
Hologic, Bedford, MA, USA). In 43 patients (20.2%),
measurements were performed at a university hospital
outside of Athens, using the same type and model of
absorptiometer as well as the same software as those in
Athens. All of the assessments were made by the same
operator in both instances, and randomization was cen-
trally performed for the entire population of the study in
the referral center in Athens. All patients had to give
informed consent prior to enrollment in the study. Full
local ethics committee approval was successfully
obtained in all sites recruiting patients for the study, and
national ethics committee approval of the trial protocol
was also obtained.
Classification of patients and randomization
T-scores were determined according to the World Health
Organization (WHO) definition as standard deviation
(SD) units from the mean BMD of 25-year-old healthy
women [12]. The BMD classifications, as defined by the
WHO, were used to operationally define patient groups
(normal = T-score of at least -1.0; osteopenia = -1 < T-
score < -2.5; osteoporosis = T-score of not more than -
2.5). In this trial, after baseline BMD measurement,
patients were classified according to the relative risk of
AIBL osteoporosis as follows: patients at low risk with a
normal BMD T-score of at least -1 in both sites received
anastrozole 1 mg/day (Arimidex™; AstraZeneca, London,
UK) only; patients at mild to moderate risk with a BMDMarkopoulos et al. Breast Cancer Research 2010, 12:R24
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T-score of less than -1 in either site but a T-score of
greater than -2.0 in both sites were randomly assigned to
receive anastrozole 1 mg/day plus oral risedronate 35 mg/
week (Actonel; sanofi-aventis, Paris, France) or anastro-
zole alone; patients at high risk with a T-score of not
more than -2.0 in LS or HP received anastrozole 1 mg/day
plus oral risedronate 35 mg/week. The classification of
patients as described above is presented in Figure 1.
Risedronate tablets were taken once a week in accor-
dance with instructions: it should be taken first thing in
the morning with 100 mL of plain water at least 30 min-
utes before the first food or drink of the day, and to mini-
mize the risk of esophageal irritation, the patient should
not lie down or recline for at least 30 minutes. Patients
were also advised not to eat or drink anything other than
plain water or to take any other medicines, including vita-
mins, calcium, or antacids, for at least 30 minutes after
taking Actonel. Additionally, all patients received daily
supplements of calcium (1,000 mg/day) and vitamin D
(400 IU/day) in accordance with the recommended
guidelines of the American Society of Clinical Oncology
[10]. BMD was then assessed at 12 and 24 months during
scheduled follow-up visits. Throughout the study, the
same densitometer was used to optimize the measure-
ments.
Statistical power and analysis
Since only two arms were randomized, in the moderate-
risk patient subgroup, the design of the study was based
on the expected difference between the two. The design
parameters were based on information available from the
1-year results of the ATAC (Arimidex, Tamoxifen Alone
or in Combination) study. In particular, in regard to the
percentage change in BMD from baseline to 12 months
for the anastrozole group in the LS and HP, the findings
from the ATAC study were -2.26% change (interquartile
range [IQR] -4.73% to -0.21%) and -1.51% change (IQR -
3.16% to 0%), respectively.
Slight amplifications of these reductions (namely, 2.75%
and 1.75% for the LS and HP, respectively) were used as
the basis for the expected difference between the two
randomized arms. The amplification was based on the
hypothesis that a BMD increase for the risedronate arm
should be expected and thus the difference would be
larger than if we assumed that the risedronate arm would
exhibit stable BMD values. For a baseline BMD value, we
used the one that corresponds to a T-score of -1.5 (the
median between the upper and lower limits defining the
intermediate-risk group).
Using the assumption that the percentage change is a
normally distributed variable, we estimated that the
reductions in absolute terms would be 0.025 in the LS
and 0.013 in the HP, with SDs of 0.031 and 0.018, respec-
tively. The SD was calculated using the property of the
normal distribution that the IQR = 1.34896 × SD.
A Bonferroni adjusted type I error rate of 2.5% for a
double-two-sided t test with 80% power was used, and 36
patients were required for each arm under the more strict
assumptions of the HP BMD expected differences (total
72) and 30 under the LS assumptions (total 60). With an
anticipated 5% dropout rate, 38 patients should be
recruited while 32 would suffice for the LS test. Study
enrollment stopped when the required number of
patients in the moderate-risk group was achieved.
A power of 79% for HP and of 86% for LS is achieved
with the sample size of 57 patients available at 12 months,
using the same assumptions as for the original design of
the study and alpha = 0.05. When using Bonferroni
adjustment, the corresponding power becomes 70% for
HP and 78% for LS.
During analysis, the Wilcoxon and signed rank non-
parametric tests were used for the univariate compari-
sons, and they were performed on the log-transformed
values of percentage change from baseline to adjust for
the presence of extreme values. In addition, mixed effects
models were used to detect time trends and time by treat-
ment interactions, taking into account both the observed
LS and HP measurements at both 12 and 24 months. The
mixed models technique uses all of the available patients
regardless of the level of missing values at the course of
time. Statistical analysis was conducted with SAS 9.1.3
statistical software (SAS Institute Inc., Cary, NC, USA).
Results
A total of 213 patients entered the study between Febru-
ary 2005 and February 2007. Among them, 93 patients
were classified as 'high-risk' patients, 70 as 'moderate-
risk' patients, and 50 having normal BMD levels as 'low-
risk' patients. Baseline characteristics are summarized in
Table 1. On average, patients' baseline characteristics
were similar among the treatment groups. ER status was
positive for 89.3% of the patients in the high-risk group,
88.0% in the low-risk group, and 90.9% in the A-only ran-
domized arm versus 97.3% in the A+R randomized arm.
Similarly, progesterone receptor status was positive for
74.2% of the patients in the high-risk group, 80.00% in the
low-risk group, and 72.7% in the A-only randomized arm
versus 70.3% in the A+R randomized arm.
In regard to BMD measurements, mean BMD values in
LS were 0.75 for the high-risk group, 1.10 for the low-risk
group, and 0.93 for the A-only randomized arm versus
0.99 for the A+R randomized arm. Mean BMD values in
HP were 0.72 for the high-risk group, 0.91 for the low-
risk group, and 0.79 for both the A-only and A+R ran-
domized arms. Median BMD levels and IQR of measure-
ments across all groups and across time are presented in
Figure 2.Markopoulos et al. Breast Cancer Research 2010, 12:R24
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Figure 1 Consort scheduled scheme of the ARBI (Arimidex Bone Mass Index and Oral Bisphosphonates) clinical trial. The number of patients 
is included in data analysis. A, anastrozole; BMD, bone mineral density; DEXA, dual-energy x-ray absorptiometry; Dis., disease; F/up, follow-up; HP, hip; 
Invest., investigator; LS, lumbar spine; R, risedronate.
Post-menopausal women with 
endocrine-responsive  
breast cancer 
n=213 
Low risk
T  -1 treated with A 
n=50 
Moderate risk
T <-1 but >-2 
randomized 
High risk
T  -2 treated with A+R 
n=93 
Treated with A only 
n=33 
Treated with A+R 
n=37 
Measurement of LS and HP   
BMD by DEXA 
Classification of groups 
Assessment of BMD at 12 and 24 months 
12 months
24 months
n=36 
n=35 
n=25 
n=21 
n=32 
n=26 
n=65 
n=50
1 Withdraw consent 
1 Dis. Recurrence 
4 Lost to F/up 
7 Missing 
1 Adverse event 
1 Withdraw consent 
1 Dis. Recurrence 
1 Lost to F/up 
3 Missing 
1 Withdraw consent 
1 Dis. Recurrence 
1 Lost to F/up 
1 Missing 
2 Adverse events 
1 Withdraw consent 
2 Invest. Decision 
3 Dis. Recurrences 
3 Deaths 
4 Lost to F/up 
13 Missing 
3 Adverse events 
1 Dis. Recurrence 
6 Lost to F/up 
5 Missing 
1 Adverse event 
1 Lost to F/up 
4 Missing 
1 Dis. Recurrence 
4 Missing 
1 Withdraw consent 
1 No baseline 
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Fracture history
Traumatic fracture history was present in seven patients:
three in the high-risk (arm, wrist, and thoracic spine),
three in the low-risk (ribs and clavicle, shin, and nose),
and one in the A+R randomized (thoracic spine) arm
(Table 1). However, in none of these cases did the fracture
occur in the HP or LS; all fractures happened between 3
to 56 years before enrollment in the study.
Comparison of randomized arms (A = 33 patients, A+R = 37 
patients)
BMD value percentage change from baseline was signifi-
cantly different for LS at 24 months (-1.5% for A versus
5.7% for A+R, Wilcoxon test P = 0.006; Figure 3) and was
statistically significantly higher from baseline for the A+R
arm (signed rank test P = 0.01; Table 2). For HP, a statisti-
cally significant decrease was observed at 24 months for
the A arm (P value = 0.02) but not for the A+R arm (P
value = 0.5) and was statistically significantly smaller for
the A arm than the A+R arm (Wilcoxon test P value =
0.037; Figure 3). At 12 months, among A-only patients, 5
(15.2%) had a T-score of less than -2.0 without becoming
osteoporotic whereas 2 (6.1%) moved to the normal BMD
region; among A+R patients, only 2 (5.4%) had a T-score
of less than -2.0 without becoming osteoporotic whereas
9 (24.3%) moved to the normal BMD region. The same
trend in BMD changes was observed at the 24-month
evaluation. It should be noted that the non-significant
changes from baseline noticed at 12 months, should be
assessed in light of the fact that the power levels achieved
with the 57 patients at 12 months are 70% for the com-
parisons involving HP and 78% for the comparisons
involving LS.
In the randomized arms, an analysis of mixed models
examined the percentage change from baseline in HP and
LS BMD values. The analyses were adjusted for the base-
line value of the outcome variable and time. In the case of
the percentage change in HP BMD value, only the base-
line value of BMD was statistically significant (Table 3). In
the case of the percentage change in LS BMD value, the
interaction of treatment arm with time is statistically sig-
nificant (Table 3, P = 0.004), and there is a statistically sig-
nificant effect of BMD value at baseline (Table 3, P = 0.
005). In regard to the significance of interaction, it means
that the treatment effect on BMD LS is not constant
across time. In particular, at 12 months, the average
c h a n g e  o f  t h e  A + R  a r m  i s  o n l y  1 . 8 %  l a r g e r  t h a n  t h e
change of the A arm (Table 3) and this is not statistically
significant (P = 0.506), whereas at 24 months, the average
Table 1: Patients' baseline characteristics
T ≤ -2, A+R
(n = 93)
-2 < T < -1, A
(n = 33)
-2 < T < -1, A+R
(n = 37)
T ≥ -1, A
(n = 50)
Mean SD Mean SD Mean SD Mean SD
Age, years 65.7 7.8 64.5 9.2 62.6 8.5 62.0 7.7
Height, cm 158.3 6.7 154.2 28.0 156.6 27.0 161.7 5.4
Weight, kg 69.6 11.2 70.5 12.4 70.6 9.6 78.2 11.3
BMD LS 
value
0.75 0.10 0.93 0.10 0.99 0.11 1.10 0.10
BMD HP 
value
0.72 0.10 0.79 0.09 0.79 0.08 0.91 0.12
Number Percentage Number Percentage Number Percentage Number Percentage
ECOG status
0 82 88.17 27 81.82 34 91.89 46 92.00
1 11 11.83 6 18.18 3 8.11 4 8.00
Fracture 
history
No 86 92.47 32 96.97 35 94.59 44 88.00
Yesa 3 3.23 0 0.0 1 2.70 3 6.00
Not reported 4 4.30 1 3.03 1 2.70 3 6.00
aTraumatic fractures only; between 3 to 56 years before enrollment in the study; none in the hip (HP) or lumbar spine (LS). A, anastrozole; BMD, 
bone mineral density; ECOG, Eastern Cooperative Oncology Group; R, risedronate; SD, standard deviation; T, T-score.Markopoulos et al. Breast Cancer Research 2010, 12:R24
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change of the A+R arm is (1.8% + 9.0% = 10.8%) larger
than the change of the A arm, and this increment (9.0%),
which increases the difference between the two arms, is
statistically significant (P = 0.004). In regard to the nega-
tive effect of the baseline values, it implies that higher
baseline BMD values correspond to smaller changes at
both 12 and 24 months whereas patients' smaller BMD
v a l u e s  a t  b a s e l i n e  e x h i b i t e d  a  h i g h e r  t r e n d  o f  B M D
increase.
Figure 2 Median bone mineral density (BMD) of lumbar spine (LS) (a) and hip (HP) (b). Error bars indicate interquartile range. A, anastrozole; R, 
risedronate.Markopoulos et al. Breast Cancer Research 2010, 12:R24
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Figure 3 Median change in bone mineral density (BMD) of lumbar spine (LS) (a) and hip (HP) (b). Error bars indicate interquartile range. A, anas-
trozole; R, risedronate (randomized arms only).Markopoulos et al. Breast Cancer Research 2010, 12:R24
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Group with T-score of not more than -2.0 in either lumbar 
spine or hip (A+R, n = 93)
A significant increase for LS at both 12 and 24 months
was detected (median increase of BMD by 6.3% and 6.6%,
respectively, P < 0.001 for both time points; Table 2) with
a corresponding non-significant change in HP (-1.9%
median change of BMD value at 12 months, P = 0.30 and
median decrease of BMD value by -1.9%, P = 0.16 at 24
months; Table 2). BMD in 13 patients (14%) improved to
the osteopenic region.
Group with T-score of at least -1 in both sites (A, n = 50)
A significant decrease was observed for LS at both 12 and
24 months (median decrease of BMD value by -5.3% and -
2.5% for LS, P < 0.001 for both time points; Table 2). For
HP, a significant reduction was observed at 12 months
but was only marginally significant at 24 months, proba-
bly due to the large between-patient variation (IQR = 13%
at 24 months versus 6.7% at 12 months) (median decrease
of BMD by -2.4%, P < 0.001 and -5.7%, P = 0.09, respec-
tively); however, only 11 patients (22%) became
osteopenic and 2 (4%) became osteoporotic. In regard to
Table 2: Descriptive statistics of bone mineral density lumbar spine and hip percentage change from baseline at 12 and 24 
months
BMD lumbar spine percentage change from baseline BMD hip percentage change from baseline
T ≤ -2, A+R -2 < T < -1, A -2 < T < -1, A+R T ≥ -1, A T ≤ -2, A+R -2 < T < -1, A -2 < T < -1, A+R T ≥ -1, A
12 months Median 6.3% 0.0% -0.4% -5.3% -1.9% -1.3% 0.0% -2.4%
IQR 12.0% 12.0% 9.2% 8.2% 11.0% 11.0% 8.6% 6.7%
P value < 0.001 0.70 0.68 < 0.001 0.30 0.22 0.76 < 0.001
24 months Median 6.6% -1.5% 5.7% -2.5% -1.9% -3.9% 1.6% -5.7%
IQR 17.0% 11.0% 14.0% 10.0% 19.0% 12.0% 15.0% 13.0%
P value < 0.001 0.25 0.01 < 0.001 0.16 0.02 0.50 0.09
A, anastrozole; BMD, bone mineral density; IQR, interquartile range; R, risedronate; T, T-score.
Table 3: Mixed models for percentage change of bone mineral density from baseline
Effect Estimate Standard error P value
Hip
Treatment arma 0.042 0.022 0.069
Time 0.004 0.022 0.838
BMD value at baseline -0.446 0.131 0.001
Lumbar spine
Treatment arma, b 0.018 0.027 0.506
Timec -0.035 0.022 0.122
Time × treatment armd 0.090 0.030 0.004
BMD value at baseline -0.328 0.113 0.005
aReference category is treatment arm A (A+R versus A). bTreatment arm effect at 12 months. cTime effect for arm A. dTreatment arm effect at 
24 months. A, anastrozole; BMD, bone mineral density; R, risedronate.Markopoulos et al. Breast Cancer Research 2010, 12:R24
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the interpretation of the non-significant differences in the
non-randomized arms, it should be noted that the study
was not designed to detect differences in this respect and
may be underpowered. However, the finding of signifi-
cant differences is an indication of sufficient power to
detect differences of the size observed.
Adverse events
Due to adverse events, seven patients stopped treatment
(Figure 1): one in the A arm and one in the A+R random-
ized arm (severe allergic skin reaction and severe myalgia,
respectively, most likely due to anastrozole) and five
patients in the A+R high-risk group (upper gastrointesti-
nal tract symptoms attributed to oral BPs). Additionally,
eight more patients among those under risedronate treat-
ment (6%) experienced mild gastrointestinal tract symp-
toms such as nausea and indigestion and 14 patients
(6.6%) suffered known anastrozole mild adverse events,
50% of which were joint pains (two patients in each of the
randomized arms, two patients in the normal BMD
region, and one osteoporotic patient). None of the
remaining events appeared more than once, and none of
the 14 adverse events was considered serious. No fragility
fractures were reported in any group of patients during
the study, and no case of osteoporosis of the jaw was
observed in any patient under risedronate treatment.
Compliance to treatment was confirmed during the inter-
view in each patient's follow-up visit; occasionally, missed
tablets of either anastrozole or risedronate were reported
by less than 10% of the patients under study treatment.
Discussion
The evolution of adjuvant endocrine therapy contributes
to the survival of postmenopausal hormone-related early
breast cancer patients. The use of AIs changed the initial
treatment with the previous gold standard of tamoxifen,
as the comparison between them and tamoxfen emerged
the efficacy of AIs in ER-dependent breast tumors' phar-
macological strategies. However, as accelerated bone loss
is associated with estrogen deficiency, AIBL is a very fre-
quent complication. Osteoporosis can be developed and
is amplified by age-related lack of estrogens, which
increases the risk of vertebral and HP fractures.
The ATAC clinical trial was the first to show that the AI
anastrozole was more effective than tamoxifen as first-
line adjuvant hormonal therapy for early-stage breast
cancer [13-15]. In the prospective bone subprotocol of
the ATAC trial (n = 308), 2 years of anastrozole signifi-
cantly reduced LS BMD by 3.97% and total HP BMD by
3.92% compared with tamoxifen [16]. After 5 years, 17%
of baseline normal BMD patients receiving anastrozole
became osteopenic. Similar changes were found in our
study. We have also observed bone loss in patients treated
with anastrozole without BP therapy (non-randomized
arm A and randomized arm A) in both sites, LS and HP,
over time. Among patients with normal BMD before
starting treatment, 11/50 (22%) became osteopenic but
only 2/50 (4%) became osteoporotic, while in the
osteopenic group of patients, the T-score was further
decreased in 5/33 cases (15.2%) but no patient became
osteoporotic.
Letrozole is also associated with an increase in fracture
risk, and in the Breast International Group (BIG) 1-98
clinical trial [17], a 40% excess of fractures was observed
in the letrozole-treated patients (8.6% versus 5.8% for
tamoxifen). Hadji and colleagues [18], in the German
bone substudy of the Tamoxifen Exemestane Adjuvant
Multicenter (TEAM) clinical trial, investigated the effect
o f  t r e a t m e n t  w i t h  e x e m e s t a n e  o n  b o n e  h e a l t h  a n d
observed an increase in bone loss at 6 months compared
with tamoxifen; bone loss was then stabilized after 6 to 12
months of treatment. Furthermore, the ALIQUOT
(Anastrozole versus Letrozole Investigation of Quality Of
Life and Tolerability) study showed that prior treatment
with tamoxifen profoundly increases the effects of AIs on
bone turnover and that these effects increase over time.
Major increases in bone turnover are seen when tamox-
ifen is stopped and then followed by anastrozole or letro-
zole administration [19].
Bone health is clearly an important concern for breast
cancer patients and, before the start of treatment, needs
to be evaluated by oncologists by using baseline DEXA
scanning and known clinical risk factors such as family
history, cigarette smoking, and excessive alcohol con-
sumption. Specific guidelines on how to evaluate and
manage cancer therapy-induced bone loss were recently
published by Hadji and colleagues [20]. AI use is a major
additional cancer treatment-related risk factor in post-
menopausal breast cancer patients. However, our find-
ings along with data from the ATAC study and the
Intergroup Exemestane Study (IES) [16,21] indicate that
women with normal BMD before starting endocrine
therapy have a very low risk of developing osteoporosis
and that only the use of general preventive measures for
maintaining bone health in postmenopausal women
seems to be appropriate practice. Nevertheless, a lot of
patients will still have established osteopenia or osteopo-
rosis and need some other intervention to minimize their
risk of ongoing loss of bone density due to long-term AI
treatment.
Prevention of continuously decreasing BMD during
endocrine treatment with AIs can be achieved with the
appropriate administration of BPs. Several clinical trials
demonstrate that the combination of AIs with BPs has a
potent effect on BMD. The Austrian Breast and Colorec-
tal Cancer Study Group trial-12 (ABCSG-12) bone sub-
study assessed zoledronic acid for preventing bone loss
during adjuvant endocrine therapy [22]. The investigatorsMarkopoulos et al. Breast Cancer Research 2010, 12:R24
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concluded that hormonal treatment for 3 years without
concomitant zoledronic acid caused significant bone loss
at the LS and trochanter (-11.3% and -7.3%, respectively)
and that the administration of BP improved BMD (LS
+4.0% and trochanter +3.9%) compared with baseline at 5
years. In three Zometa-Femara Adjuvant Synergy Trials
(Z-FAST, ZO-FAST, and E-ZO-FAST), patients received
letrozole therapy combined with either immediate or
delayed (that is, after a fracture or after BMD T-score
decreased to -2.0) zoledronic acid treatment [23-25].
Patients who have been administrated immediately with
zoledronic acid treatment had significant increases in
BMD and had fewer fractures overall than patients who
have delayed treatment (P < 0.0001 for all).
Considering oral administration of BPs, Lester and col-
leagues [26], in the ARIBON (Arimidex Bondronate)
study, reported that, after 2 years, osteopenic patients
treated with monthly doses of oral ibandronate gained
+2.98% (range -8.9 to +19.9) and +0.60% (range -9.0 to
+6.9) at the LS and HP, respectively. Patients treated with
placebo, however, lost -3.22% (range -16.0 to +4.3) at the
LS and -3.90% (range -12.3 to +7.2) at the HP. Addition-
ally, a recently published report of the Study of Anastro-
zole with the Bisphosphonate Risedronate (SABRE)
reported that oral risedronate 35 mg weekly results in
favorable effects in BMD [27]. The SABRE study demon-
strated that, in postmenopausal women who are at risk of
fragility fracture and who are receiving adjuvant anastro-
zole, the addition of risedronate led to a 1% to 3%
increase in LS BMD and a 1% to 2% increase in total HP
BMD during a period of 24 months. Bone turnover mark-
ers were also measured and found to be suppressed by 3
months in patients receiving risedronate [27]. Our find-
ings are in agreement with data from these studies. The
addition of 35 mg oral risedronate weekly to anastrozole
treatment in osteopenic patients (randomized arm A+R)
resulted in a significant increase in BMD. Moreover, in
the non-randomly assigned group of patients (T-score of
not more than -2.0) who were all treated with risedronate,
a significant increase for BMD at LS was detected, with a
number of patients moving from osteoporotic to the
osteopenic region. However, the statistically significant
increase for BMD at HP found in the SABRE trial at 24
months was not detected in this non-randomly assigned
arm in our trial, showing a mild numerical decrease at the
same time point.
All of the above data support the common perception
that bone protection with a BP is required for patients
with osteoporosis. However, there is still a controversy on
the management of patients with osteopenia. Among our
osteopenic group of patients (randomized arm A) receiv-
ing additionally only daily supplements of calcium and
vitamin D, the T-score became less than -2 in only 5/33
cases (15.2%), but no patient became osteoporotic (T-
score of less than -2.5) during the 2 years of our study. On
the other hand, the addition of 35 mg oral risedronate
weekly to anastrozole treatment in osteopenic patients
(randomized arm A+R) resulted in a significant increase
in BMD, with 9/37 patients (24.3%) moving to the normal
BMD region. In the medical community, a healthy life-
style and adequate intake of calcium and vitamin D, along
with 12 to 24 months of evaluation of BMD by DEXA, are
acceptable ways of managing this group of patients with
mild to moderate osteopenia. However, data from a num-
ber of studies and our findings presented here indicate
that BPs might also be used in order to prevent further
bone loss in this patient population.
Overall tolerability of oral administration of BPs in our
study was good, with only five patients (4%) stopping
treatment with risedronate due to upper gastrointestinal
tract symptoms and eight more patients (6%) experienc-
ing mild symptoms such as nausea and indigestion. No
case of osteonecrosis of the jaw (ONJ) was observed in
any patient under risedronate treatment. Notably, long-
term BP therapy is associated with ONJ, although its esti-
mated frequency in patients taking oral BPs for osteopo-
rosis is less than 1 case per 100,000 person-years of
exposure [28].
Finally, there is also a fascinating trend toward the
potential adjuvant benefit of BPs in the improvement of
clinical outcome of patients with early-stage breast can-
cer [29-31] and the reduction of breast cancer risk as well
[32,33]. However, it is too early to consider BPs either in
the prevention or in the adjuvant treatment setting until
more data become available from large prospective trials
[34].
Conclusions
O u r  f i n d i n g s  s u g g e s t  t h a t  p a t i e n t s  w i t h  n o r m a l  B M D
before starting treatment with anastrozole have a very
low risk to develop osteoporosis during the first 2 years of
treatment; general preventive measures such as healthy
lifestyle and daily supplements of calcium and vitamin D
seem to be adequate treatment for retaining bone health
in this group of patients, which has a 20% chance to
develop osteopenia only. On the other hand, the addition
of oral risedronate in postmenopausal breast cancer
patients in the high-risk region (T-score of not more than
-2.0) receiving anastrozole has a significant increase in
BMD levels. Bone protection with a BP is certainly indi-
cated for patients with established osteoporosis. For
patients at mild to moderate risk (-2.0 < T-score < -1), the
combination of both therapies (anastrozole plus oral rise-
dronate) might also be used in order to prevent bone loss.
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